Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
  • Payor
Campus
  • Payor

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

Learn more
ESC/EAS 2019 Guidelines for the management of dyslipidaemias

ESC/EAS 2019 Guidelines for the management of dyslipidaemias

Learn more
Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery

Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery

Learn more
VTE Risk Assessment in Surgical Patients

VTE Risk Assessment in Surgical Patients

Learn more
Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Learn more
Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Learn more
Odyssey Outcomes - PVD Sub-analysis

Odyssey Outcomes - PVD Sub-analysis

Learn more
Why compromise for less: Should PCSK9 inhibitors be initial therapy?

Why compromise for less: Should PCSK9 inhibitors be initial therapy?

Learn more
Odyssey Outcomes - Total Events Analysis

Odyssey Outcomes - Total Events Analysis

Learn more
Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS

Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS

Learn more
Odyssey outcomes - CVOT mortality sub-analysis

Odyssey outcomes - CVOT mortality sub-analysis

Learn more
LLTs Exposure Time and Major Vascular Risk Reduction

LLTs Exposure Time and Major Vascular Risk Reduction

Learn more